Seres Therapeutics, Inc.
MCRB
$19.44
$1.126.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -99.95% | -99.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -99.95% | -99.71% |
| Cost of Revenue | 11.34% | -49.74% | -75.75% | -84.64% | -86.92% |
| Gross Profit | -11.34% | -138.12% | -187.09% | -47.15% | 52.61% |
| SG&A Expenses | -22.97% | -34.40% | -36.64% | -40.77% | -32.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.01% | -40.87% | -46.93% | -50.36% | -48.03% |
| Operating Income | 24.01% | -71.54% | -18.18% | 3.31% | 2.38% |
| Income Before Tax | 60.06% | 3.06% | -25.33% | -7.75% | 12.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.06% | 3.06% | -25.33% | -7.75% | 12.12% |
| Earnings from Discontinued Operations | 612.62% | 746.30% | 1,041.71% | 1,845.52% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 153.03% | 188.23% | 100.12% | 81.97% | -5.66% |
| EBIT | 24.01% | -71.54% | -18.18% | 3.31% | 2.38% |
| EBITDA | 23.90% | -81.51% | -20.16% | 3.30% | 2.49% |
| EPS Basic | 147.77% | 176.82% | 99.85% | 79.79% | 4.73% |
| Normalized Basic EPS | 44.26% | -35.75% | 8.71% | 6.76% | 20.71% |
| EPS Diluted | 147.42% | 175.51% | 99.47% | 79.81% | 5.09% |
| Normalized Diluted EPS | 44.28% | -33.93% | 9.39% | 7.28% | 21.09% |
| Average Basic Shares Outstanding | 21.02% | 22.04% | 21.40% | 14.47% | 10.92% |
| Average Diluted Shares Outstanding | 21.06% | 21.60% | 20.90% | 13.99% | 10.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |